The global demand for DNA Repair Drugs Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
DNA damage causes alteration of structure in genetic material. It causes the inclusion of deficiencies and abnormalities in the DNA structure, which leads to mutations in the DNA. The mutations take place in the genes coding for essential proteins or enzymes. Thus DNA damage hampers the proper functioning and performance of the DNA resulting in the development of genetic disorders. However, the human body is capable of repairing damaged DNA sequences. DNA repairing is a combination of processes altogether that includes identification of cells where the mutation has occurred and the correction of DNA molecules that are involved in the encoding genome. Certain drugs such as poly ADP ribose polymerase (PARP) inhibitors are used to enhance the body's DNA repairing mechanism. DNA repair drugs support the treatments related to DNA damage and genetic abnormalities.
The prevalence of cancer is rising rapidly across the globe. Mutations in the genes cause uncontrolled cell growth leading to cancer. Cancer is one of the major diseases responsible for a large number of deaths across the globe. The increasing prevalence of cancer is propelling the global DNA repair drugs market. Furthermore, the growing adoption of advanced next-generation technologies to treat cancer and other genetic diseases is fueling demand. The key manufacturers are investing in R & D on a large scale to find effective drug solutions to support the DNA repair mechanism. The strategies acquired by key market players are propelling the global market. COVID-19 pandemic is supporting the R & D in drug development that is likely to enhance the global DNA repair drugs market.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of DNA repair drugs.
The entire DNA repair drugs market has been sub-categorized into drug, mechanism of action and application. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Mechanism of Action
- Base Excision Repair (BER)
- Homologous Recombination (HR)
- Mismatch Repair (MMR)
- Ovarian Cancer
- Breast Cancer
This section covers regional segmentation which accentuates on current and future demand for DNA repair drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global DNA Repair Drugs Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the DNA repair drugs market include Artios Pharma, AstraZeneca, Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline, Clovis Oncology, Pfizer Inc.. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.